A Phase 3 interventional study of lapatinib and paclitaxel in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Terminated at 16 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.
Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 37th largest by enrollment, is one of 9 that started in 2005, is one of 18 in phase 3, and was the 16th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 70 · Phase 3 18
First in 2003; this study’s year is marked. 9 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 35 across the 114 interventional studies. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 96th largest by enrollment of the 155 interventional ones that give a count, is one of 10 that started in 2005, is one of 45 in phase 3, and was the 24th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 114 studies testing lapatinib in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study was originally designed as a Phase III randomized, double blind, placebo controlled study to assess the safety and tolerability, and efficacy of paclitaxel plus trastuzumab plus lapatinib compared with paclitaxel plus trastuzumab plus placebo in women with ErbB2 overexpressing metastatic breast cancer. The planned study was a two stage design with an initial open-label safety stage to be conducted in approximately 65 subjects followed by a randomized phase conducted in a further 700 subjects. The open-label part of the study sequentially enrolled three cohorts with patients receiving a different dose combination of paclitaxel, trastuzumab and lapatinib. Following poor recruitment rate in the open label stage, the randomized stage of the study was terminated, thus no subjects were enrolled into the randomization stage.
The primary objective of this study was to evaluate and compare time to progression (TTP). The Primary objective for open label phase was to determine the safety and tolerability of lapatinib when administered in combination with both paclitaxel and trastuzumab. The study first enrolled an open label safety cohort of 20 patients to assess the tolerability of the triplet combination. This was a 1 arm, 3 cohort study stage.
Open-label Phase: Patients were sequentially enrolled into three cohorts and received an open-label combination of paclitaxel, trastuzumab and lapatinib: Cohort 1 received paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle, trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly, and lapatinib 1000 mg PO daily. Cohort 2 received paclitaxel 70mg/m2 IV weekly for 3 weeks of a 4 week cycle, trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly, and lapatinib 1000 mg PO daily. Cohort 3 paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle, trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly, and lapatinib 750 mg PO daily.
Randomized Phase: was terminated following the poor recruitment rate in the open-label safety stage. No subjects were enrolled into the randomization stage.
In summary, at approximately 3.5 years the primary analysis which included demographics, efficacy and safety were conducted; at approximately 7 years protocol amendment 7 cancelled collection of efficacy endpoints, and only key safety endpoints were to be collected; the final analysis was performed at approximately 14 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received: paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily
Drug: lapatinib · Drug: paclitaxel · Drug: trastuzumab
Participants received paclitaxel 70mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily.
Drug: lapatinib · Drug: paclitaxel · Drug: trastuzumab
Participants in this arm received 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 750 mg PO
Drug: lapatinib · Drug: paclitaxel · Drug: trastuzumab
(GW572016) 1000 mg QD
80 mg/m2 IV weekly for three weeks
4 mg/kg loading dose and 2 mg/kg weekly IV
Extent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Mean/Standard Deviation
Extent of exposure is defined as the duration of the treatment administered during the study. The mean duration of exposure to lapatinib, trastuzumab and paclitaxel is calculated as the number of weeks between the start and end of treatment.
Time frame: From the date of the first dose of the investigational product to end of study, up to approx. 14 years
Extent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Median/Min-Max
Extent of exposure is defined as the duration of the treatment administered during the study. The mean duration of exposure to lapatinib, trastuzumab and paclitaxel is calculated as the number of weeks between the start and end of treatment.
Time frame: From the date of the first dose of the investigational product to end of study, up to approx. 14 years
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment was exercised in deciding whether reporting was appropriate in other situations. Refer to the general AE/SAE module for a list of non-serious AEs and SAEs.
Time frame: From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 14 years
Number of Participants Who Died Due to Any Cause
Number of participants who died due to any cause throughout the study including off-treatment deaths (on-treatment deaths are reported for the All-Cause Mortality in the AE section).
Time frame: From the date of the first dose of investigational product until last patient last visit, up to approximately 14 years
Number of Events of Diarrhea With the Indicated Characteristics
Events of diarrhea are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.
Time frame: From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years
Number of Events of Rash With the Indicated Characteristics
Events of rash are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.
Time frame: From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years
Number of Participants With the Maximum Toxicity Grade for the Indicated Clinical Hematology Parameters
Blood samples for clinical laboratory evaluation were taken at Baseline prior to the administration of investigational product and thereafter at each scheduled visit. Haematology parameters included haemoglobin, total white blood cell count (WBC), neutrophils, lymphocytes and platelets. Hematology data was summarized by the National Cancer Institute's Common toxicity criteria for adverse events (NCI CTCAE) toxicity grade (Version 3.0). Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death.
Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Number of Participants With the Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters
Blood samples for clinical laboratory evaluation were taken at Baseline prior to the administration of investigational product and thereafter at each scheduled visit. Clinical chemistry parameters included values \> upper limit of normal (ULN)=Hyper; values \< lower limit of normal (LLN)=Hypo of sodium (Hypernatraemia and Hyponatraemia), potassium (Hyperkalaemia and Hypokalaemia), calcium (Hypercalcaemia and Hypocalcaemia), glucose (Hyperglycaemia and Hyperglycaemia), creatinine (if \>2 milligram per deciliter \[mg/dL\]), aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phophatase, total bilirubin (if available bilirubin fractionation is recommended if the total bilirubin is \> twice of ULN), and albumin. Clinical chemistry data was summarized by National Cancer Institute's Common toxicity criteria for adverse events (NCI CTCAE) toxicity grade (Version 3.0). Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death.
Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Number of Events of Hepatotoxicity With the Indicated Characteristics
Events of hepatotoxicity are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.
Time frame: From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years
Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at the Indicated Time Points
Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Change From Baseline in Heart Rate at the Indicated Time Points
Heart rate was measured at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Change From Baseline in Body Temperature at the Indicated Time Points
Body temperature was measured at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Number of Participants With at Least 1 Event of Left Ventricular Ejection Fraction Decrease With the Indicated Characteristics
Events of left ventricular ejection fraction (LVEF) decrease were based on the number of participants who had an actual event and was characterized as serious, related to investigational product, leading to withdrawal from the study and/or fatal.
Time frame: Baseline and every 8 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Number of Participants With the Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status Value
The Eastern Cooperative Oncology Group (ECOG) performance status scales and grades/criteria are used to assess how a participant's disease is progressing, to assess how the disease affects the daily living abilities of the participant, and to determine appropriate treatment and prognosis. Grade 0, fully active, able to carry on all pre-disease performance without restriction. Grade 1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. Grade 2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about more than 50% of waking hours. Grade 3, capable of only limited selfcare; confined to bed or chair more than 50% of waking hours. Grade 4, completely disabled; cannot carry on any selfcare; totally confined to bed or chair. Grade 5, dead.
Time frame: Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Number of Participants Who Received Any Concomitant Medications During the Study Period
Number of participants who received any concomitant medication along with study drugs (lapatinib, trastuzumab and paclitaxel) were counted during the treatment period.
Time frame: withdrawal/study completion, up to approx. 3.5 years
Overall Response (OR): Percentage of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator
OR is defined as the number of participants achieving either a CR or PR, per Response Evaluation Criteria in Solid Tumors (RECIST). The best OR is defined as the best response recorded from the start of treatment until progressive disease (PD)/recurrence. CR is defined as the disappearance of all target lesions (TLs) and non-TLs. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL(s), as assessed by the IRC. PD is defined as at least a 20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs. Responses were confirmed at subsequent assessments made \>=28 days after the original response. Participants with an unknown or missing response are treated as non-responders.
Time frame: From the date of the first dose of investigational product to end of study, up to approx. 7 years
Time to Response as Assessed by the Investigator
Time to Response was defined for subjects who had a confirmed CR or PR as the time from first dose until first documented evidence of partial or complete tumour response (whichever status was recorded first). CR is defined as the disappearance of all TLs \& non-TLs. PR is defined as at least a 30% decrease in the sum of the LD of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL(s). PD is defined as at least a 20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs.
Time frame: From the date of the first dose of investigational product until the first documented evidence of a PR or CR, up to approx. 7 years
Duration of Response (DoR), as Assessed by the Investigator
DoR is defined for the subset of participants who had a confirmed CR (disappearance of all TLs and non-TLs) or PR (\>=30% decrease in the sum of the LD of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL\[s\]) as the time from the first documented evidence of a CR or PR until the first documentation of radiological PD or death due to breast cancer, if sooner. PD is defined as \>=20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs. For participants who did not progress or die, DoR was censored on the date of the last radiological scan. If a participant had only a Baseline visit or did not have a date of a radiological scan that was later than the date of initiation of anti-cancer therapy, DoR was censored at the start date of treatment.
Time frame: From the first documented evidence of a PR or CR until the earlier of the date of disease progression or the date of death due to breast cancer, up to approx. 7 years
Percentage of Participants With Clinical Benefit (Complete Response (CR), Partial Response (PR), and Stable Disease [SD] for at Least 24 Weeks) as Assessed by Investigator
Clinical benefit is defined as the percentage of participants achieving either a CR or PR or SD (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of the LD of target lesions, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions), taking as reference, the smallest sum LD since the treatment started) for at least 24 weeks. This was based on confirmed responses from the investigator assessment of clinical benefit.
Time frame: From the date of the first dose of investigational product until the first documented evidence of a PR or CR or SD until the earlier of the date of disease progression or the date of death due to breast cancer, up to approx. 7 years
Progression-free Survival as Assessed by the Investigator
Progression-free survival is defined as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. Disease progression was based on the investigator's assessments of the objective evidence (e.g., radiological scans and medical photographs). For participants who do not progress, or die, progression-free survival was censored at the time of the last investigator assessed radiological scan preceding the initiation of any alternative anti-cancer therapy. Progression-free survival was summarized using Kaplan-Meier curves.
Time frame: From the date of the first dose of investigational product until the earlier of the date of disease progression or death due to any cause, up to approx. 7 years
Female participants (par.) with histologically confirmed invasive breast cancer (Stage IV disease) whose tumors overexpressed the ErbB2 protein, documented by either Immunohistochemistry (IHC) or fluorescence in situ hybridisation (FISH), were eligible for inclusion in this study.
| Milestone | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Started | 29 | 14 | 20 |
| Completed | 20 | 10 | 9 |
| Not completed | 9 | 4 | 11 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 3 |
| Withdrew: Sponsor terminated study | 0 | 1 | 1 |
| Withdrew: Disease progression | 1 | 1 | 2 |
| Withdrew: Non-compliant- study visits, trtmnts, req. surgery | 2 | 1 | 4 |
| Withdrew: Death | 1 | 0 | 0 |
Extent of exposure is defined as the duration of the treatment administered during the study. The mean duration of exposure to lapatinib, trastuzumab and paclitaxel is calculated as the number of weeks between the start and end of treatment.
| Weeks | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Lapatinib | 70.9 ± 115.44 | 93.1 ± 147.92 | 82.5 ± 135.79 |
| Trastuzumab | 60.7 ± 72.07 | 72.2 ± 88.66 | 62.3 ± 75.52 |
| Paclitaxel | 26.9 ± 16.88 | 29.4 ± 23.00 | 23.8 ± 14.87 |
Extent of exposure is defined as the duration of the treatment administered during the study. The mean duration of exposure to lapatinib, trastuzumab and paclitaxel is calculated as the number of weeks between the start and end of treatment.
| Weeks | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Lapatinib | 33.0 (3 to 615) | 38.5 (2 to 547) | 32.5 (1 to 574) |
| Trastuzumab | 33.0 (2 to 343) | 37.0 (2 to 271) | 31.5 (1 to 245) |
| Paclitaxel | 22.0 (2 to 86) | 23.5 (2 to 94) | 22.0 (1 to 63) |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment was exercised in deciding whether reporting was appropriate in other situations. Refer to the general AE/SAE module for a list of non-serious AEs and SAEs.
| Participants | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Any AEs | 29 | 14 | 20 |
| Any SAEs | 14 | 6 | 5 |
Number of participants who died due to any cause throughout the study including off-treatment deaths (on-treatment deaths are reported for the All-Cause Mortality in the AE section).
| Participants | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Number of Participants Who Died Due to Any Cause | 12 | 2 | 1 |
Events of diarrhea are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.
| Events of diarrhea | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Any Event | 358 | 90 | 37 |
| Serious | 4 | 0 | 0 |
| Related to investigational product | 347 | 75 | 26 |
| Leading to withdrawal from study | 2 | 1 | 1 |
| Fatal | 0 | 0 | 0 |
Events of rash are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.
| Events of rash | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Any Event | 69 | 23 | 20 |
| Serious | 2 | 0 | 0 |
| Related to investigational product | 55 | 12 | 7 |
| Leading to withdrawal from study | 3 | 0 | 0 |
| Fatal | 0 | 0 | 0 |
Blood samples for clinical laboratory evaluation were taken at Baseline prior to the administration of investigational product and thereafter at each scheduled visit. Haematology parameters included haemoglobin, total white blood cell count (WBC), neutrophils, lymphocytes and platelets. Hematology data was summarized by the National Cancer Institute's Common toxicity criteria for adverse events (NCI CTCAE) toxicity grade (Version 3.0). Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death.
| Participants | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Haemaglobin, Grade 1 | 19 | 11 | 11 |
| Haemaglobin, Grade 2 | 7 | 1 | 6 |
| Haemaglobin, Grade 3 | 2 | 0 | 1 |
| Haemaglobin, Grade 4 | 1 | 0 | 0 |
| Platelets, Grade 1 | 3 | 0 | 0 |
| Platelets, Grade 2 | 1 | 0 | 0 |
| Platelets, Grade 3 | 0 | 0 | 0 |
| Platelets, Grade 4 | 1 | 0 | 0 |
| Total WBC, Grade 1 | 10 | 6 | 7 |
| Total WBC, Grade 2 | 8 | 4 | 2 |
| Total WBC, Grade 3 | 3 | 1 | 4 |
| Total WBC, Grade 4 | 1 | 0 | 0 |
| Neutrophils, Grade 1 | 7 | 2 | 5 |
| Neutrophils, Grade 2 | 7 | 4 | 4 |
| Neutrophils, Grade 3 | 3 | 1 | 5 |
| Neutrophils, Grade 4 | 3 | 0 | 0 |
| Lymphocytes, Grade 1 | 5 | 3 | 7 |
| Lymphocytes, Grade 2 | 10 | 4 | 4 |
| Lymphocytes, Grade 3 | 5 | 3 | 1 |
| Lymphocytes, Grade 4 | 1 | 0 | 1 |
Blood samples for clinical laboratory evaluation were taken at Baseline prior to the administration of investigational product and thereafter at each scheduled visit. Clinical chemistry parameters included values \> upper limit of normal (ULN)=Hyper; values \< lower limit of normal (LLN)=Hypo of sodium (Hypernatraemia and Hyponatraemia), potassium (Hyperkalaemia and Hypokalaemia), calcium (Hypercalcaemia and Hypocalcaemia), glucose (Hyperglycaemia and Hyperglycaemia), creatinine (if \>2 milligram per deciliter \[mg/dL\]), aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phophatase, total bilirubin (if available bilirubin fractionation is recommended if the total bilirubin is \> twice of ULN), and albumin. Clinical chemistry data was summarized by National Cancer Institute's Common toxicity criteria for adverse events (NCI CTCAE) toxicity grade (Version 3.0). Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death.
| Participants | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Hypernatraemia, Grade 1 | 0 | 1 | 1 |
| Hypernatraemia, Grade 2 | 1 | 0 | 0 |
| Hypernatraemia, Grade 3 | 0 | 0 | 0 |
| Hypernatraemia, Grade 4 | 0 | 0 | 0 |
| Hyponatraemia, Grade 1 | 8 | 1 | 1 |
| Hyponatraemia, Grade 2 | 0 | 0 | 0 |
| Hyponatraemia, Grade 3 | 0 | 1 | 0 |
| Hyponatraemia, Grade 4 | 0 | 0 | 0 |
| Hyperkalaemia, Grade 1 | 2 | 0 | 0 |
| Hyperkalaemia, Grade 2 | 2 | 1 | 1 |
| Hyperkalaemia, Grade 3 | 0 | 0 | 0 |
| Hyperkalaemia, Grade 4 | 1 | 0 | 1 |
| Hypokalaemia, Grade 1 | 11 | 6 | 6 |
| Hypokalaemia, Grade 2 | 0 | 0 | 0 |
| Hypokalaemia, Grade 3 | 6 | 2 | 0 |
| Hypokalaemia, Grade 4 | 0 | 0 | 0 |
| Hypercalcaemia, Grade 1 | 1 | 0 | 0 |
| Hypercalcaemia, Grade 2 | 0 | 0 | 0 |
| Hypercalcaemia, Grade 3 | 0 | 0 | 0 |
| Hypercalcaemia, Grade 4 | 0 | 0 | 0 |
| Hypocalcaemia, Grade 1 | 10 | 3 | 4 |
| Hypocalcaemia, Grade 2 | 7 | 2 | 3 |
| Hypocalcaemia, Grade 3 | 3 | 0 | 1 |
| Hypocalcaemia, Grade 4 | 0 | 0 | 0 |
| Hyperglycaemia, Grade 1 | 15 | 9 | 6 |
| Hyperglycaemia, Grade 2 | 3 | 3 | 2 |
| Hyperglycaemia, Grade 3 | 5 | 0 | 2 |
| Hyperglycaemia, Grade 4 | 0 | 0 | 0 |
| Hypoglycemia, Grade 1 | 5 | 2 | 2 |
| Hypoglycemia, Grade 2 | 0 | 1 | 1 |
| Hypoglycemia, Grade 3 | 0 | 0 | 0 |
| Hypoglycemia, Grade 4 | 0 | 0 | 0 |
| Albumin, Grade 1 | 5 | 3 | 1 |
| Albumin, Grade 2 | 3 | 0 | 0 |
| Albumin, Grade 3 | 1 | 0 | 0 |
| Albumin, Grade 4 | 0 | 0 | 0 |
| Total Bilirubin, Grade 1 | 2 | 1 | 3 |
| Total Bilirubin, Grade 2 | 2 | 2 | 1 |
| Total Bilirubin, Grade 3 | 1 | 1 | 0 |
| Total Bilirubin, Grade 4 | 0 | 0 | 0 |
| Creatinine, Grade 1 | 2 | 0 | 0 |
| Creatinine, Grade 2 | 2 | 0 | 0 |
| Creatinine, Grade 3 | 1 | 0 | 0 |
| Creatinine, Grade 4 | 0 | 0 | 0 |
| Alkaline Phophatase, Grade 1 | 14 | 3 | 5 |
| Alkaline Phophatase, Grade 2 | 2 | 0 | 0 |
| Alkaline Phophatase, Grade 3 | 2 | 0 | 0 |
| Alkaline Phophatase, Grade 4 | 0 | 0 | 0 |
| ALT, Grade 1 | 7 | 1 | 3 |
| ALT, Grade 2 | 3 | 3 | 2 |
| ALT, Grade 3 | 0 | 0 | 0 |
| ALT, Grade 4 | 0 | 0 | 0 |
| AST, Grade 1 | 6 | 3 | 6 |
| AST, Grade 2 | 1 | 1 | 0 |
| AST, Grade 3 | 1 | 1 | 0 |
| AST, Grade 4 | 0 | 0 | 0 |
Events of hepatotoxicity are characterized as serious, related to investigational product, leading to withdrawal from the study and fatal. Participants could have been counted in more than one category.
| Events of hepatotoxicity | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Any Event | 6 | — | 2 |
| Serious | 0 | — | 0 |
| Related to investigational product | 5 | — | 0 |
| Leading to withdrawal from study | 0 | — | 0 |
| Fatal | 0 | — | 0 |
Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Millimeter of mercury (mmHg) | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| SBP, Week 4 | 0.5 ± 16.29 | -7.2 ± 20.70 | -3.9 ± 22.76 |
| SBP, Week 8 | 4.6 ± 12.35 | -8.6 ± 22.25 | -2.7 ± 24.73 |
| SBP, Week 12 | 3.2 ± 18.46 | -6.9 ± 17.09 | -9.3 ± 23.54 |
| SBP, Week 16 | 0.8 ± 18.10 | -6.6 ± 15.26 | -7.9 ± 24.43 |
| SBP, Week 20 | 1.7 ± 17.80 | -11.5 ± 14.69 | -13.8 ± 25.15 |
| SBP, Week 24 | 2.9 ± 13.87 | -1.8 ± 11.81 | -7.8 ± 26.06 |
| SBP, Week 28 | 2.3 ± 19.10 | -5.7 ± 20.38 | -5.2 ± 10.71 |
| SBP, Week 32 | 3.2 ± 23.11 | -16.4 ± 10.03 | -6.3 ± 5.51 |
| SBP, Week 36 | 1.6 ± 15.85 | -8.7 ± 12.19 | -26.7 ± 37.75 |
| SBP, Week 40 | -2.2 ± 24.44 | -3.4 ± 9.62 | -34.0 ± 38.18 |
| SBP, Week 44 | 2.7 ± 14.47 | -3.8 ± 9.83 | -38.0 ± 32.53 |
| SBP, Week 48 | 6.5 ± 18.76 | -6.7 ± 11.18 | -84.0 ± NA |
| SBP, Week 52 | 7.7 ± 14.47 | -3.8 ± 24.78 | — |
| SBP, Week 56 | 8.4 ± 13.53 | -8.2 ± 18.74 | — |
| SBP, Week 60 | 9.3 ± 22.07 | -17.0 ± 9.31 | — |
| SBP, Week 64 | 3.5 ± 16.53 | -11.3 ± 11.24 | — |
| SBP, Week 68 | 0.1 ± 10.71 | -6.5 ± 12.02 | — |
| SBP, Week 72 | 7.1 ± 13.25 | -20.0 ± NA | — |
| SBP, Week 76 | 4.5 ± 12.96 | — | — |
| SBP, Week 80 | 8.7 ± 6.92 | — | — |
| SBP, Week 84 | 7.0 ± 20.20 | — | — |
| SBP, Week 88 | -2.7 ± 16.32 | — | — |
| SBP, Week 92 | 10.4 ± 16.59 | — | — |
| SBP, Week 96 | -0.5 ± 4.12 | — | — |
| SBP, Week 100 | 10.8 ± 7.53 | — | — |
| SBP, Week 104 | 7.0 ± 16.00 | — | — |
| SBP, Week 108 | 4.6 ± 7.89 | — | — |
| SBP, Week 112 | 12.3 ± 10.72 | — | — |
| SBP, Week 116 | 9.3 ± 15.22 | — | — |
| SBP, Week 120 | 13.3 ± 19.86 | — | — |
| SBP, Week 124 | 7.3 ± 8.50 | — | — |
| SBP, Week 128 | -11.0 ± 9.90 | — | — |
| SBP, Week 132 | -10.5 ± 10.61 | — | — |
| SBP, Week 136 | -4.0 ± 18.38 | — | — |
| SBP, Week 140 | 4.5 ± 23.33 | — | — |
| SBP, Week 144 | 10.0 ± 0 | — | — |
| SBP, Week 148 | 25.0 ± NA | — | — |
| SBP, Withdrawal/Study Conclusion | 0.5 ± 16.13 | -1.3 ± 15.64 | 7.0 ± 20.28 |
| SBP, 30 Day Follow-up | 2.4 ± 19.18 | -3.9 ± 17.03 | 13.8 ± 19.25 |
| DBP, Week 4 | -2.5 ± 10.36 | -3.9 ± 10.50 | -4.8 ± 11.10 |
| DBP, Week 8 | -0.6 ± 11.41 | -8.9 ± 11.54 | -1.2 ± 12.46 |
| DBP, Week 12 | -0.3 ± 10.19 | -6.2 ± 10.37 | -4.2 ± 12.87 |
| DBP, Week 16 | -3.4 ± 12.98 | -3.2 ± 8.42 | -4.4 ± 15.18 |
| DBP, Week 20 | -3.0 ± 12.65 | -1.6 ± 9.53 | -9.1 ± 13.65 |
| DBP, Week 24 | -1.2 ± 11.30 | -1.8 ± 6.56 | -5.2 ± 13.08 |
| DBP, Week 28 | -1.8 ± 14.27 | -2.1 ± 8.15 | -2.0 ± 5.05 |
| DBP, Week 32 | -2.2 ± 13.70 | -6.3 ± 10.24 | -4.7 ± 6.51 |
| DBP, Week 36 | -7.2 ± 6.48 | -3.3 ± 6.40 | -10.7 ± 11.02 |
| DBP, Week 40 | -9.3 ± 11.36 | -0.7 ± 13.76 | -8.0 ± 19.80 |
| DBP, Week 44 | -9.0 ± 6.59 | -2.3 ± 10.33 | -19.5 ± 6.36 |
| DBP, Week 48 | -3.9 ± 7.57 | -0.2 ± 8.13 | -34.0 ± NA |
| DBP, Week 52 | -7.4 ± 13.46 | -3.0 ± 12.33 | — |
| DBP, Week 56 | -5.1 ± 8.62 | -3.4 ± 7.99 | — |
| DBP, Week 60 | -3.6 ± 11.56 | -6.3 ± 6.24 | — |
| DBP, Week 64 | -7.7 ± 12.27 | -5.3 ± 8.54 | — |
| DBP, Week 68 | -11.0 ± 6.40 | -3.5 ± 7.78 | — |
| DBP, Week 72 | 3.0 ± 9.26 | -16.0 ± NA | — |
| DBP, Week 76 | -4.8 ± 5.00 | — | — |
| DBP, Week 80 | -3.5 ± 5.58 | — | — |
| DBP, Week 84 | -5.8 ± 9.50 | — | — |
| DBP, Week 88 | -9.3 ± 11.48 | — | — |
| DBP, Week 92 | -3.8 ± 5.26 | — | — |
| DBP, Week 96 | -7.3 ± 6.29 | — | — |
| DBP, Week 100 | -4.4 ± 6.50 | — | — |
| DBP, Week 104 | -4.6 ± 9.10 | — | — |
| DBP, Week 108 | -2.0 ± 5.89 | — | — |
| DBP, Week 116 | -8.5 ± 9.33 | — | — |
| DBP, Week 120 | -6.0 ± 7.94 | — | — |
| DBP, Week 124 | -6.0 ± 6.00 | — | — |
| DBP, Week 128 | -12.5 ± 0.71 | — | — |
| DBP, Week 132 | -14.5 ± 4.95 | — | — |
| DBP, Week 136 | -17.0 ± 4.24 | — | — |
| DBP, Week 140 | -7.5 ± 10.61 | — | — |
| DBP, Week 144 | 0.0 ± 0 | — | — |
| DBP, Week 148 | 1.0 ± NA | — | — |
| DBP, Withdrawal/Study Conclusion | -0.5 ± 11.39 | -0.4 ± 12.08 | 2.1 ± 8.64 |
| DBP, 30 Day Follow-up | -0.8 ± 11.96 | 0.8 ± 11.62 | 3.2 ± 9.98 |
Heart rate was measured at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Beats per minute (BPM) | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Week 4 | -1.714 ± 10.9099 | -3.417 ± 26.3593 | 3.333 ± 12.1268 |
| Week 8 | -5.667 ± 14.7908 | -3.231 ± 16.8481 | 5.353 ± 10.7642 |
| Week 12 | -0.217 ± 10.7109 | -0.417 ± 15.6812 | -2.875 ± 10.6074 |
| Week 16 | -0.478 ± 13.4667 | 2.625 ± 15.1369 | -1.917 ± 10.9084 |
| Week 24 | -0.476 ± 16.7768 | -5.300 ± 15.1808 | 5.167 ± 10.2843 |
| Week 28 | -4.313 ± 16.0155 | -1.429 ± 17.7281 | 3.600 ± 8.5615 |
| Week 32 | -4.933 ± 16.6496 | -0.500 ± 11.1098 | 0.333 ± 10.5987 |
| Week 36 | -5.000 ± 13.0128 | 4.857 ± 18.4791 | 7.000 ± 11.5326 |
| Week 40 | -1.000 ± 14.1614 | -3.571 ± 17.6149 | -2.500 ± 9.1924 |
| Week 44 | -3.000 ± 11.1624 | -5.000 ± 17.9778 | -0.500 ± 10.6066 |
| Week 48 | -5.500 ± 8.1955 | -2.500 ± 12.9422 | -14.000 ± NA |
| Week 52 | -1.889 ± 14.4866 | -2.000 ± 11.8533 | — |
| Week 56 | -2.000 ± 13.4907 | -2.000 ± 15.2151 | — |
| Week 60 | -2.600 ± 13.3766 | 1.500 ± 15.0222 | — |
| Week 64 | -4.667 ± 16.1245 | 0.000 ± 15.3840 | — |
| Week 68 | -8.286 ± 21.1638 | 1.000 ± 25.4558 | — |
| Week 72 | -0.714 ± 21.0295 | 19.000 ± NA | — |
| Week 76 | -0.500 ± 16.6463 | — | — |
| Week 80 | 0.800 ± 14.4810 | — | — |
| Week 84 | 9.200 ± 21.1234 | — | — |
| Week 88 | 2.200 ± 24.6110 | — | — |
| Week 92 | -2.400 ± 10.1390 | — | — |
| Week 96 | -8.250 ± 7.6322 | — | — |
| Week 100 | -6.750 ± 13.1751 | — | — |
| Week 104 | -6.800 ± 15.3525 | — | — |
| Week 108 | -8.750 ± 6.4485 | — | — |
| Week 112 | -0.667 ± 15.0444 | — | — |
| Week 116 | -4.667 ± 14.5717 | — | — |
| Week 120 | -7.667 ± 9.4516 | — | — |
| Week 124 | -5.333 ± 13.2035 | — | — |
| Week 128 | 1.000 ± 21.2132 | — | — |
| Week 132 | -4.000 ± 14.1421 | — | — |
| Week 136 | -4.000 ± 15.5563 | — | — |
| Week 140 | -3.500 ± 16.2635 | — | — |
| Week 144 | 3.000 ± NA | — | — |
| Week 148 | 6.000 ± NA | — | — |
| Withdrawal/Study Conclusion | -1.435 ± 19.3481 | -7.900 ± 19.3990 | 7.750 ± 9.8814 |
| 30 Day Follow-up | 0.560 ± 13.1564 | -7.889 ± 17.3526 | 13.200 ± 11.6060 |
Body temperature was measured at Baseline and every 4 weeks thereafter up to withdrawal/study completion and at the 30 day follow-up visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Degree Celsius | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Week 4 | -0.229 ± 0.5062 | -0.242 ± 0.3605 | 0.078 ± 0.5976 |
| Week 8 | 0.011 ± 0.5250 | -0.154 ± 0.4294 | 0.247 ± 0.4652 |
| Week 12 | 0.021 ± 0.4374 | -0.567 ± 0.4960 | 0.173 ± 0.4636 |
| Week 16 | -0.052 ± 0.5814 | -0.127 ± 0.4880 | 0.121 ± 0.5494 |
| Week 20 | 0.018 ± 0.5712 | -0.238 ± 0.4138 | 0.300 ± 0.3536 |
| Week 24 | 0.157 ± 0.5006 | -0.100 ± 0.4138 | 0.017 ± 0.5193 |
| Week 28 | -0.094 ± 0.4956 | -0.529 ± 0.4751 | 0.300 ± 0.3536 |
| Week 32 | -0.156 ± 0.6077 | -0.237 ± 0.2134 | 0.000 ± 0.2000 |
| Week 36 | -0.215 ± 0.5728 | -0.129 ± 0.3946 | 0.533 ± 0.3786 |
| Week 40 | 0.045 ± 0.4634 | -0.314 ± 0.1952 | 0.450 ± 0.9192 |
| Week 44 | -0.182 ± 0.4729 | -0.217 ± 0.3920 | 0.250 ± 0.0707 |
| Week 48 | -0.109 ± 0.4571 | -0.200 ± 0.1414 | 0.300 ± NA |
| Week 52 | -0.222 ± 1.0616 | -0.340 ± 0.3286 | — |
| Week 56 | 0.111 ± 0.6489 | -0.240 ± 0.6427 | — |
| Week 60 | -0.070 ± 0.5889 | -0.225 ± 0.2754 | — |
| Week 64 | -0.080 ± 0.4662 | -0.150 ± 0.1732 | — |
| Week 68 | 0.286 ± 0.6744 | -0.550 ± 0.0707 | — |
| Week 72 | 0.057 ± 0.7390 | -0.400 ± NA | — |
| Week 76 | 0.017 ± 0.4834 | — | — |
| Week 80 | -0.150 ± 0.6442 | — | — |
| Week 84 | 0.067 ± 0.5610 | — | — |
| Week 88 | -0.267 ± 0.4131 | — | — |
| Week 92 | -0.200 ± 0.8155 | — | — |
| Week 96 | -0.125 ± 0.4573 | — | — |
| Week 100 | -0.100 ± 0.9083 | — | — |
| Week 104 | -0.160 ± 0.7436 | — | — |
| Week 108 | 0.080 ± 0.6099 | — | — |
| Week 112 | 0.050 ± 0.5000 | — | — |
| Week 116 | 0.250 ± 0.6403 | — | — |
| Week 120 | 0.200 ± 0.4359 | — | — |
| Week 124 | 0.167 ± 0.8083 | — | — |
| Week 128 | 0.200 ± 1.4142 | — | — |
| Week 132 | -0.150 ± 1.2021 | — | — |
| Week 136 | 0.000 ± 1.2728 | — | — |
| Week 140 | 0.450 ± 1.3435 | — | — |
| Week 144 | 1.300 ± NA | — | — |
| Week 148 | 0.700 ± NA | — | — |
| Withdrawal/Study Conclusion | -0.083 ± 0.6833 | -0.020 ± 0.4367 | 0.237 ± 0.5999 |
| 30 Day Follow-up | -0.092 ± 0.6238 | -0.400 ± 0.5074 | 0.140 ± 0.5320 |
Events of left ventricular ejection fraction (LVEF) decrease were based on the number of participants who had an actual event and was characterized as serious, related to investigational product, leading to withdrawal from the study and/or fatal.
| Participants | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Number of Participants With at Least 1 Event of Left Ventricular Ejection Fraction Decrease With the Indicated Characteristics | 8 | 2 | 0 |
The Eastern Cooperative Oncology Group (ECOG) performance status scales and grades/criteria are used to assess how a participant's disease is progressing, to assess how the disease affects the daily living abilities of the participant, and to determine appropriate treatment and prognosis. Grade 0, fully active, able to carry on all pre-disease performance without restriction. Grade 1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. Grade 2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about more than 50% of waking hours. Grade 3, capable of only limited selfcare; confined to bed or chair more than 50% of waking hours. Grade 4, completely disabled; cannot carry on any selfcare; totally confined to bed or chair. Grade 5, dead.
| Participants | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Screening, Grade 3 | 0 | 0 | 0 |
| Screening, Grade 4 | 0 | 0 | 0 |
| Screening, Grade 5 | 0 | 0 | 0 |
| Day 1 pre-dose, Grade 3 | 0 | 0 | 0 |
| Day 1 pre-dose, Grade 4 | 0 | 0 | 0 |
| Day 1 pre-dose, Grade 5 | 0 | 0 | 0 |
| Week 4, Grade 3 | 0 | 0 | 0 |
| Week 4, Grade 4 | 0 | 0 | 0 |
| Week 4, Grade 5 | 0 | 0 | 0 |
| Week 8, Grade 3 | 0 | 0 | 0 |
| Week 8, Grade 4 | 0 | 0 | 0 |
| Week 8, Grade 5 | 0 | 0 | 0 |
| Week 12, Grade 3 | 0 | 0 | 0 |
| Week 12, Grade 4 | 0 | 0 | 0 |
| Week 12, Grade 5 | 0 | 0 | 0 |
| Week 16, Grade 3 | 0 | 0 | 0 |
| Week 16, Grade 4 | 0 | 0 | 0 |
| Week 16, Grade 5 | 0 | 0 | 0 |
| Week 20, Grade 3 | 0 | 0 | 0 |
| Week 20, Grade 4 | 0 | 0 | 0 |
| Week 20, Grade 5 | 0 | 0 | 0 |
| Week 24, Grade 3 | 0 | 0 | 0 |
| Week 24, Grade 4 | 0 | 0 | 0 |
| Week 24, Grade 5 | 0 | 0 | 0 |
| Week 28, Grade 3 | 0 | 0 | 0 |
| Week 28, Grade 4 | 0 | 0 | 0 |
| Week 28, Grade 5 | 0 | 0 | 0 |
| Week 32, Grade 3 | 0 | 0 | 0 |
| Week 32, Grade 4 | 0 | 0 | 0 |
| Week 32, Grade 5 | 0 | 0 | 0 |
| Week 36, Grade 3 | 0 | 0 | 0 |
| Week 36, Grade 4 | 0 | 0 | 0 |
| Week 36, Grade 5 | 0 | 0 | 0 |
| Week 40, Grade 3 | 0 | 0 | 0 |
| Week 40, Grade 4 | 0 | 0 | 0 |
| Week 40, Grade 5 | 0 | 0 | 0 |
| Week 44, Grade 3 | 0 | 0 | 0 |
| Week 44, Grade 4 | 0 | 0 | 0 |
| Week 44, Grade 5 | 0 | 0 | 0 |
| Week 48, Grade 3 | 0 | 0 | 0 |
| Week 48, Grade 4 | 0 | 0 | 0 |
| Week 48, Grade 5 | 0 | 0 | 0 |
| Week 52, Grade3 | 0 | 0 | — |
| Week 52, Grade4 | 0 | 0 | — |
| Week 52, Grade5 | 0 | 0 | — |
| Week 56, Grade 3 | 0 | 0 | — |
| Week 56, Grade 4 | 0 | 0 | — |
| Week 56, Grade 5 | 0 | 0 | — |
| Week 60, Grade 3 | 0 | 0 | — |
| Week 60, Grade 4 | 0 | 0 | — |
| Week 60, Grade 5 | 0 | 0 | — |
| Week 64, Grade 3 | 0 | 0 | — |
| Week 64, Grade 4 | 0 | 0 | — |
| Week 64, Grade 5 | 0 | 0 | — |
| Week 68, Grade3 | 0 | 0 | — |
| Week 68, Grade4 | 0 | 0 | — |
| Week 68, Grade5 | 0 | 0 | — |
| Week 72, Grade 3 | 0 | 0 | — |
| Week 72, Grade 4 | 0 | 0 | — |
| Week 72, Grade 5 | 0 | 0 | — |
| Week 76, Grade3 | 0 | — | — |
| Week 76, Grade4 | 0 | — | — |
| Week 76, Grade5 | 0 | — | — |
| Week 80, Grade 3 | 0 | — | — |
| Week 80, Grade 4 | 0 | — | — |
| Week 80, Grade 5 | 0 | — | — |
| Week 84, Grade 3 | 0 | — | — |
| Week 84, Grade 4 | 0 | — | — |
| Week 84, Grade 5 | 0 | — | — |
| Week 88, Grade 3 | 0 | — | — |
| Week 88, Grade 4 | 0 | — | — |
| Week 88, Grade 5 | 0 | — | — |
| Week 92, Grade 3 | 0 | — | — |
| Week 92, Grade 4 | 0 | — | — |
| Week 92, Grade 5 | 0 | — | — |
| Week 96, Grade 3 | 0 | — | — |
| Week 96, Grade 4 | 0 | — | — |
| Week 96, Grade 5 | 0 | — | — |
| Week 100, Grade 3 | 0 | — | — |
| Week 100, Grade 4 | 0 | — | — |
| Week 100, Grade 5 | 0 | — | — |
| Week 104, Grade 3 | 0 | — | — |
| Week 104, Grade 4 | 0 | — | — |
| Week 104, Grade 5 | 0 | — | — |
| Week 108, Grade 3 | 0 | — | — |
| Week 108, Grade 4 | 0 | — | — |
| Week 108, Grade 5 | 0 | — | — |
| Week 112, Grade 3 | 0 | — | — |
| Week 112, Grade 4 | 0 | — | — |
| Week 112, Grade 5 | 0 | — | — |
| Week 116, Grade 3 | 0 | — | — |
| Week 116, Grade 4 | 0 | — | — |
| Week 116, Grade 5 | 0 | — | — |
| Week 120, Grade 3 | 0 | — | — |
| Week 120, Grade 4 | 0 | — | — |
| Week 120, Grade 5 | 0 | — | — |
| Week 124, Grade 3 | 0 | — | — |
| Week 124, Grade 4 | 0 | — | — |
| Week 124, Grade 5 | 0 | — | — |
| Week 128, Grade 3 | 0 | — | — |
| Week 128, Grade 4 | 0 | — | — |
| Week 128, Grade 5 | 0 | — | — |
| Week 132, Grade 3 | 0 | — | — |
| Week 132, Grade 4 | 0 | — | — |
| Week 132, Grade 5 | 0 | — | — |
| Week 136, Grade 3 | 0 | — | — |
| Week 136, Grade 4 | 0 | — | — |
| Week 136, Grade 5 | 0 | — | — |
| Week 140, Grade 3 | 2 | — | — |
| Week 140, Grade 4 | 0 | — | — |
| Week 140, Grade 5 | 0 | — | — |
| Week 144, Grade 3 | 0 | — | — |
| Week 144, Grade 4 | 0 | — | — |
| Week 144, Grade 5 | 0 | — | — |
| Week 148, Grade 3 | 0 | — | — |
| Week 148, Grade 4 | 0 | — | — |
| Week 148, Grade 5 | 0 | — | — |
| Withdrawal/Study conclusion, Grade 3 | 0 | 0 | 0 |
| Withdrawal/Study conclusion, Grade 4 | 0 | 0 | 0 |
| Withdrawal/Study conclusion, Grade 5 | 0 | 0 | 0 |
Number of participants who received any concomitant medication along with study drugs (lapatinib, trastuzumab and paclitaxel) were counted during the treatment period.
| Participants | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Number of Participants Who Received Any Concomitant Medications During the Study Period | 29 | 14 | 20 |
OR is defined as the number of participants achieving either a CR or PR, per Response Evaluation Criteria in Solid Tumors (RECIST). The best OR is defined as the best response recorded from the start of treatment until progressive disease (PD)/recurrence. CR is defined as the disappearance of all target lesions (TLs) and non-TLs. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL(s), as assessed by the IRC. PD is defined as at least a 20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs. Responses were confirmed at subsequent assessments made \>=28 days after the original response. Participants with an unknown or missing response are treated as non-responders.
| Percentage of participants | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Overall Response (OR): Percentage of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator | 79.3 (64.6 to 94.1) | 71.4 (47.8 to 95.1) | 70.0 (49.9 to 90.1) |
Time to Response was defined for subjects who had a confirmed CR or PR as the time from first dose until first documented evidence of partial or complete tumour response (whichever status was recorded first). CR is defined as the disappearance of all TLs \& non-TLs. PR is defined as at least a 30% decrease in the sum of the LD of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL(s). PD is defined as at least a 20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs.
| Participants | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Week 8 | 15 | 8 | 8 |
| Week 12 | 5 | 1 | 1 |
| Week 16 | 2 | 1 | 3 |
| Week 20 | 0 | 0 | 1 |
| Week 24 | 1 | 0 | 0 |
| Week 28 | 0 | 0 | 1 |
DoR is defined for the subset of participants who had a confirmed CR (disappearance of all TLs and non-TLs) or PR (\>=30% decrease in the sum of the LD of TLs, taking as a reference the Baseline sum LD and no PD, or complete resolution of TLs and the persistence of one or more non-TL\[s\]) as the time from the first documented evidence of a CR or PR until the first documentation of radiological PD or death due to breast cancer, if sooner. PD is defined as \>=20% increase in the sum of the LD of TLs, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-TLs. For participants who did not progress or die, DoR was censored on the date of the last radiological scan. If a participant had only a Baseline visit or did not have a date of a radiological scan that was later than the date of initiation of anti-cancer therapy, DoR was censored at the start date of treatment.
| Weeks | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Duration of Response (DoR), as Assessed by the Investigator | 56.6 (27.6 to 117.7) | 59.0 (33.1 to 88.7) | 70.6 (31.4 to 103.1) |
Clinical benefit is defined as the percentage of participants achieving either a CR or PR or SD (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of the LD of target lesions, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions), taking as reference, the smallest sum LD since the treatment started) for at least 24 weeks. This was based on confirmed responses from the investigator assessment of clinical benefit.
| Percentage of Participants | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Percentage of Participants With Clinical Benefit (Complete Response (CR), Partial Response (PR), and Stable Disease [SD] for at Least 24 Weeks) as Assessed by Investigator | 79.3 (64.6 to 94.1) | 71.4 (47.8 to 95.1) | 70.0 (49.9 to 90.1) |
Progression-free survival is defined as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. Disease progression was based on the investigator's assessments of the objective evidence (e.g., radiological scans and medical photographs). For participants who do not progress, or die, progression-free survival was censored at the time of the last investigator assessed radiological scan preceding the initiation of any alternative anti-cancer therapy. Progression-free survival was summarized using Kaplan-Meier curves.
| Weeks | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| Progression-free Survival as Assessed by the Investigator | 64.7 (33.1 to 117) | 55.0 (20.4 to 96.1) | 78.4 (31.9 to 111) |
Collected over Adverse Events (AEs) and Serious adverse events (SAEs) were collected from the first dose of investigational product to 30 days after the last dose of investigational product, up to approx.12 years (maximum exposure to Lapatinib (615 weeks) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Paclitaxel 80mg/Trastuzumab 4 mg/Lapatinib 1000mg | 0/29 (0%) | 14/29 (48.3%) | 29/29 (100%) |
| Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | 0/14 (0%) | 6/14 (42.9%) | 13/14 (92.9%) |
| Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg | 0/20 (0%) | 5/20 (25%) | 20/20 (100%) |
| Event | Cohort 1: Paclitaxel 80mg/Trastuzumab 4 mg/Lapatinib 1000mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 5/29 | 0/14 | 1/20 |
| CellulitisInfections and infestations | 0/29 | 2/14 | 0/20 |
| Left ventricular dysfunctionCardiac disorders | 2/29 | 1/14 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 2/29 | 1/14 | 0/20 |
| Drug hypersensitivityImmune system disorders | 0/29 | 1/14 | 0/20 |
| PneumoniaInfections and infestations | 0/29 | 1/14 | 1/20 |
| Ejection fraction decreasedInvestigations | 2/29 | 1/14 | 0/20 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/29 | 1/14 | 1/20 |
| NeutropeniaBlood and lymphatic system disorders | 2/29 | 0/14 | 0/20 |
| HypokalaemiaMetabolism and nutrition disorders | 2/29 | 0/14 | 0/20 |
| Event | Cohort 1: Paclitaxel 80mg/Trastuzumab 4 mg/Lapatinib 1000mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 28/29 | 13/14 | 15/20 |
| RashSkin and subcutaneous tissue disorders | 25/29 | 9/14 | 17/20 |
| FatigueGeneral disorders | 21/29 | 12/14 | 13/20 |
| NauseaGastrointestinal disorders | 16/29 | 11/14 | 13/20 |
| AlopeciaSkin and subcutaneous tissue disorders | 22/29 | 8/14 | 11/20 |
| VomitingGastrointestinal disorders | 17/29 | 6/14 | 4/20 |
| ConstipationGastrointestinal disorders | 7/29 | 7/14 | 5/20 |
| InsomniaPsychiatric disorders | 6/29 | 7/14 | 3/20 |
| Mucosal inflammationGeneral disorders | 8/29 | 6/14 | 2/20 |
| Upper respiratory tract infectionInfections and infestations | 8/29 | 6/14 | 3/20 |
| Age, Continuous(Years) | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg | Total |
|---|---|---|---|---|
| Mean | 51.5 ± 11.08 | 56.1 ± 11.92 | 52.2 ± 13.00 | 52.7 ± 11.84 |
| Sex: Female, Male(Participants) | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg | Total |
|---|---|---|---|---|
| Female | 29 | 14 | 20 | 63 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg | Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg | Total |
|---|---|---|---|---|
| African American/African Heritage | 7 | 2 | 4 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| White - White/Caucasian/European Heritage | 22 | 11 | 16 | 49 |
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2005 to primary completion in Jul 2009, 43 months.
Results were first posted in Aug 2014, 5 years after primary completion. A results delay was requested in Aug 2010.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lapatinib · Paclitaxel